A Phase 2 interventional study of IMC-1121B (ramucirumab) and Dacarbazine in Metastatic Malignant Melanoma, sponsored by Eli Lilly and Company. Completed at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-01.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Melanoma by Eli Lilly and Company — none open to participants now, 1 under way, none of them phase 3. Melanoma · Eli Lilly and Company.
Among the 14 studies in Melanoma by Eli Lilly and Company, this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2007, is one of 3 in phase 2, and was the 3rd registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →None of the 14 studies in Melanoma by Eli Lilly and Company is open now. The open studies under Melanoma, anywhere →
Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 40 across 2,650 interventional studies indexed under Melanoma.
Median enrollment 130 across the 13 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Melanoma by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to determine the progression-free survival (PFS) of participants with previously untreated metastatic malignant melanoma when treated with IMC-1121B (ramucirumab) alone or in combination with dacarbazine.
The purpose of this study is to determine the antitumor activity and safety profile of IMC-1121B (ramucirumab) when used alone or in combination with dacarbazine in participants with metastatic melanoma who have not received prior chemotherapy for this disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IMC-1121B (ramucirumab)
Biological: IMC-1121B (ramucirumab)
IMC-1121B (ramucirumab) + dacarbazine
Biological: IMC-1121B (ramucirumab) · Drug: Dacarbazine
10 milligrams/kilogram (mg/kg) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
Also known as: ramucirumab, LY3009806
1000 milligrams/square meter (mg/m2) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
Also known as: DIC, Imidazole, Carboxamide
Progression Free Survival (PFS)
PFS was defined as the time from the first day of therapy to the first evidence of disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.0) or death from any cause. Progressive disease (PD) was defined as at least a 20% increase in the sum of the longest diameter (LD) of the target lesions, taking as reference the smallest sum LD recorded since the treatment started in comparison with the measurement of the nadir or the appearance of 1 or more new lesions. In addition, unequivocal progression of existing non-target lesions was considered PD. New or existing pleural effusion/ascites required cytological confirmation for PD according to the protocol. Participants who did not progress and who were alive or did not have documented progression or missed ≥2 visits, or had no post baseline assessment were censored at the day of their last tumor assessment.
Time frame: Baseline up to 36 months
Number of Participants With Adverse Events (AE)
The number of participants who experienced any IMC-1121B (ramucirumab \[RAM\]) treatment-related and treatment emergent AE (TEAE), treatment-related TEAE of Grade ≥3, treatment-related TE serious AEs (SAEs), treatment-related TEAE resulting in death (Grade 5 AE) and any TEAEs resulting in death. A summary of SAEs and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
Time frame: Baseline up to 40 months
Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]
The ORR was defined as the percentage of all randomized participants with the best overall response of PR or CR using Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR was defined as the disappearance of all target and non-target lesions. PR was defined as at least a 30% decrease in sum of longest diameter of target lesions. CR and PR had to be confirmed by repeat assessments and performed no fewer than 4 weeks after the criteria for response were first met.
Time frame: Cycle 1 Day 1 (of 21-day cycle) up to 17.1 months
Duration of Response
The duration of overall response was defined as the time from first assessment of complete response (CR) or partial response (PR) to the first date of progressive disease (PD) using Response Evaluation Criteria in Solid Tumors (RECIST v1.0), initiation of other or additional antitumor therapy, or death from any cause. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. CR and PR had to be confirmed by repeat assessments and performed no fewer than 4 weeks after the criteria for response were first met. PD was defined as at least 20% increase in sum of longest diameter of target lesions. Participants who did not relapse were censored at the day of their last objective tumor assessment.
Time frame: Cycle 1 Day 1 (of 21-day cycle) up to 17.1 months
Percentage of Participants With Stable Disease (SD) or Better (Disease Control Rate) at 6 Weeks
Disease Control Rate (DCR) was defined as complete response (CR) plus partial response (PR) plus SD using Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR was defined as the disappearance of all target and non-target lesions and the normalization of non-target lesion tumor marker levels. PR was defined as at least a 30% decrease from baseline in sum of longest diameter of target lesions. CR and PR had to be confirmed by repeat assessments and performed no fewer than 4 weeks after the criteria for response were first met. SD was defined as: neither sufficient increase to qualify for progressive disease (PD) nor sufficient shrinkage to qualify for PR, taking as reference the smallest sum of the longest diameters recorded since treatment began. PD was defined as at least 20% increase in sum of longest diameter of target lesions.
Time frame: 6 weeks (2 cycles of treatment)
Percentage of Participants With Stable Disease (SD) or Better (Disease Control Rate) at 12 Weeks
Disease Control Rate (DCR) was defined as complete response (CR) plus partial response (PR) plus SD using Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR was defined as the disappearance of all target and non-target lesions and the normalization of non-target lesion tumor marker levels. PR was defined as at least a 30% decrease from baseline in sum of longest diameter of target lesions. CR and PR had to be confirmed by repeat assessments and performed no fewer than 4 weeks after the criteria for response were first met. Stable Disease (SD) was defined as: neither sufficient increase to qualify for progressive disease (PD) nor sufficient shrinkage to qualify for PR, taking as reference the smallest sum of the longest diameters recorded since treatment began. PD was defined as at least 20% increase in sum of longest diameter of target lesions.
Time frame: 12 weeks (4 cycles of treatment)
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Response Rate) at 12 Weeks
Response rate was defined as a CR or a PR using Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR was defined as the disappearance of all target and non-target lesions and the normalization of non-target lesion tumor marker levels. PR was defined as at least a 30% decrease from baseline in sum of longest diameter of target lesions. CR and PR had to be confirmed by repeat assessments and performed no fewer than 4 weeks after the criteria for response were first met.
Time frame: 12 weeks (4 cycles of treatment)
Maximum Concentration (Cmax) for Cycle 1 Day 1
Cmax was not calculated due to sparse sampling.
Time frame: Cycle 1 Day 1 (21-day cycle) 1-hour post infusion
Maximum Concentration (Cmax) for Cycle 1 Day 7
Cmax was not calculated due to sparse sampling.
Time frame: Cycle 1 Day 7 (21-day cycle)
Maximum Concentration (Cmax) for Cycle 1 Day 14
Cmax was not calculated due to sparse sampling.
Time frame: Cycle 1 Day 14 (21-day cycle)
| Milestone | IMC-1121B (Ramucirumab) + Dacarbazine | IMC-1121B (Ramucirumab) |
|---|---|---|
| Started | 54 | 52 |
| Received any quantity of study drug | 52 | 50 |
| Completed | 49 | 50 |
| Not completed | 5 | 2 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Withdrew: Found ineligible after randomization | 2 | 1 |
PFS was defined as the time from the first day of therapy to the first evidence of disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.0) or death from any cause. Progressive disease (PD) was defined as at least a 20% increase in the sum of the longest diameter (LD) of the target lesions, taking as reference the smallest sum LD recorded since the treatment started in comparison with the measurement of the nadir or the appearance of 1 or more new lesions. In addition, unequivocal progression of existing non-target lesions was considered PD. New or existing pleural effusion/ascites required cytological confirmation for PD according to the protocol. Participants who did not progress and who were alive or did not have documented progression or missed ≥2 visits, or had no post baseline assessment were censored at the day of their last tumor assessment.
| months | IMC-1121B (Ramucirumab) + Dacarbazine | IMC-1121B (Ramucirumab) |
|---|---|---|
| Progression Free Survival (PFS) | 2.6 (1.4 to 5.4) | 1.7 (1.4 to 2.9) |
The number of participants who experienced any IMC-1121B (ramucirumab \[RAM\]) treatment-related and treatment emergent AE (TEAE), treatment-related TEAE of Grade ≥3, treatment-related TE serious AEs (SAEs), treatment-related TEAE resulting in death (Grade 5 AE) and any TEAEs resulting in death. A summary of SAEs and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
| participants | IMC-1121B (Ramucirumab) + Dacarbazine | IMC-1121B (Ramucirumab) |
|---|---|---|
| Any RAM related TEAE | 43 | 40 |
| RAM related SAE | 9 | 5 |
| RAM related ≥ Grade 3 AE | 20 | 13 |
| RAM related death | 1 | 1 |
| RAM related TEAE leading to discontinuation of RAM | 3 | 4 |
| Any AE with outcome of death | 2 | 2 |
The ORR was defined as the percentage of all randomized participants with the best overall response of PR or CR using Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR was defined as the disappearance of all target and non-target lesions. PR was defined as at least a 30% decrease in sum of longest diameter of target lesions. CR and PR had to be confirmed by repeat assessments and performed no fewer than 4 weeks after the criteria for response were first met.
| percentage of participants | IMC-1121B (Ramucirumab) + Dacarbazine | IMC-1121B (Ramucirumab) |
|---|---|---|
| Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] | 17.3 (8.2 to 30.3) | 4.0 (0.5 to 13.7) |
The duration of overall response was defined as the time from first assessment of complete response (CR) or partial response (PR) to the first date of progressive disease (PD) using Response Evaluation Criteria in Solid Tumors (RECIST v1.0), initiation of other or additional antitumor therapy, or death from any cause. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. CR and PR had to be confirmed by repeat assessments and performed no fewer than 4 weeks after the criteria for response were first met. PD was defined as at least 20% increase in sum of longest diameter of target lesions. Participants who did not relapse were censored at the day of their last objective tumor assessment.
| months | IMC-1121B (Ramucirumab) + Dacarbazine | IMC-1121B (Ramucirumab) |
|---|---|---|
| Duration of Response | 11.0 (3.9 to 17.1) | NA (3.2 to 14.0) |
Disease Control Rate (DCR) was defined as complete response (CR) plus partial response (PR) plus SD using Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR was defined as the disappearance of all target and non-target lesions and the normalization of non-target lesion tumor marker levels. PR was defined as at least a 30% decrease from baseline in sum of longest diameter of target lesions. CR and PR had to be confirmed by repeat assessments and performed no fewer than 4 weeks after the criteria for response were first met. SD was defined as: neither sufficient increase to qualify for progressive disease (PD) nor sufficient shrinkage to qualify for PR, taking as reference the smallest sum of the longest diameters recorded since treatment began. PD was defined as at least 20% increase in sum of longest diameter of target lesions.
| percentage of participants | IMC-1121B (Ramucirumab) + Dacarbazine | IMC-1121B (Ramucirumab) |
|---|---|---|
| Percentage of Participants With Stable Disease (SD) or Better (Disease Control Rate) at 6 Weeks | 54 | 44 |
Disease Control Rate (DCR) was defined as complete response (CR) plus partial response (PR) plus SD using Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR was defined as the disappearance of all target and non-target lesions and the normalization of non-target lesion tumor marker levels. PR was defined as at least a 30% decrease from baseline in sum of longest diameter of target lesions. CR and PR had to be confirmed by repeat assessments and performed no fewer than 4 weeks after the criteria for response were first met. Stable Disease (SD) was defined as: neither sufficient increase to qualify for progressive disease (PD) nor sufficient shrinkage to qualify for PR, taking as reference the smallest sum of the longest diameters recorded since treatment began. PD was defined as at least 20% increase in sum of longest diameter of target lesions.
| percentage of participants | IMC-1121B (Ramucirumab) + Dacarbazine | IMC-1121B (Ramucirumab) |
|---|---|---|
| Percentage of Participants With Stable Disease (SD) or Better (Disease Control Rate) at 12 Weeks | 40 | 24 |
Response rate was defined as a CR or a PR using Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR was defined as the disappearance of all target and non-target lesions and the normalization of non-target lesion tumor marker levels. PR was defined as at least a 30% decrease from baseline in sum of longest diameter of target lesions. CR and PR had to be confirmed by repeat assessments and performed no fewer than 4 weeks after the criteria for response were first met.
| percentage of participants | IMC-1121B (Ramucirumab) + Dacarbazine | IMC-1121B (Ramucirumab) |
|---|---|---|
| Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Response Rate) at 12 Weeks | 13.5 | 4.0 |
Cmax was not calculated due to sparse sampling.
No measurements were reported for this outcome.
Cmax was not calculated due to sparse sampling.
No measurements were reported for this outcome.
Cmax was not calculated due to sparse sampling.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IMC-1121B (Ramucirumab) + Dacarbazine | — | 14/52 (26.9%) | 52/52 (100%) |
| IMC-1121B (Ramucirumab) | — | 15/50 (30%) | 48/50 (96%) |
| Event | IMC-1121B (Ramucirumab) + Dacarbazine | IMC-1121B (Ramucirumab) |
|---|---|---|
| Infusion related reactionGeneral disorders | 0/52 | 3/50 |
| Abdominal painGastrointestinal disorders | 0/52 | 2/50 |
| Hepatic failureHepatobiliary disorders | 0/52 | 2/50 |
| Coronary artery diseaseCardiac disorders | 0/52 | 1/50 |
| Myocardial infarctionCardiac disorders | 0/52 | 1/50 |
| Supraventricular tachycardiaCardiac disorders | 0/52 | 1/50 |
| VomitingGastrointestinal disorders | 0/52 | 1/50 |
| JaundiceHepatobiliary disorders | 0/52 | 1/50 |
| DehydrationMetabolism and nutrition disorders | 0/52 | 1/50 |
| Back painMusculoskeletal and connective tissue disorders | 0/52 | 1/50 |
| Event | IMC-1121B (Ramucirumab) + Dacarbazine | IMC-1121B (Ramucirumab) |
|---|---|---|
| FatigueGeneral disorders | 33/52 | 28/50 |
| ThrombocytopeniaBlood and lymphatic system disorders | 20/52 | 4/50 |
| NauseaGastrointestinal disorders | 20/52 | 14/50 |
| NeutropeniaBlood and lymphatic system disorders | 18/52 | 0/50 |
| HeadacheNervous system disorders | 9/52 | 16/50 |
| ConstipationGastrointestinal disorders | 16/52 | 10/50 |
| Oedema peripheralGeneral disorders | 15/52 | 10/50 |
| AnorexiaMetabolism and nutrition disorders | 14/52 | 7/50 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 14/52 | 4/50 |
| HypertensionVascular disorders | 12/52 | 12/50 |
All enrolled participants who were treated with any quantity of study drug.
| Age, Categorical(Participants) | IMC-1121B (Ramucirumab) + Dacarbazine | IMC-1121B (Ramucirumab) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 29 | 28 | 57 |
| >=65 years | 23 | 22 | 45 |
| Sex: Female, Male(Participants) | IMC-1121B (Ramucirumab) + Dacarbazine | IMC-1121B (Ramucirumab) | Total |
|---|---|---|---|
| Female | 15 | 12 | 27 |
| Male | 37 | 38 | 75 |
| Ethnicity (NIH/OMB)(Participants) | IMC-1121B (Ramucirumab) + Dacarbazine | IMC-1121B (Ramucirumab) | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 1 | 6 |
| Not Hispanic or Latino | 47 | 49 | 96 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | IMC-1121B (Ramucirumab) + Dacarbazine | IMC-1121B (Ramucirumab) | Total |
|---|---|---|---|
| United States | 52 | 50 | 102 |
| Race(participants) | IMC-1121B (Ramucirumab) + Dacarbazine | IMC-1121B (Ramucirumab) | Total |
|---|---|---|---|
| Asian | 1 | 0 | 1 |
| White | 50 | 50 | 100 |
| Other | 1 | 0 | 1 |
The record gives a start of Nov 2007, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 3 years 1 month after primary completion. A results delay was requested in Sep 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ramucirumab